Compare · EYPT vs MTD
EYPT vs MTD
Side-by-side comparison of EyePoint Inc. (EYPT) and Mettler-Toledo International Inc. (MTD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EYPT and MTD operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- MTD is the larger of the two at $23.01B, about 24.0x EYPT ($960.0M).
- Over the past year, EYPT is up 28.5% and MTD is down 4.9% - EYPT leads by 33.4 points.
- EYPT has been more active in the news (3 items in the past 4 weeks vs 2 for MTD).
- MTD has more recent analyst coverage (23 ratings vs 9 for EYPT).
- Company
- EyePoint Inc.
- Mettler-Toledo International Inc.
- Price
- $11.46-2.55%
- $1137.86-1.41%
- Market cap
- $960.0M
- $23.01B
- 1M return
- -14.54%
- -13.68%
- 1Y return
- +28.48%
- -4.94%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 3
- 2
- Recent ratings
- 9
- 23
EyePoint Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
Latest EYPT
- Chief Financial Officer Elston George converted options into 7,500 shares and covered exercise/tax liability with 3,627 shares, increasing direct ownership by 4% to 91,691 units (SEC Form 4) (withholding obligation)
- EyePoint Announces Participation at Upcoming Investor Conferences
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
- SEC Form 10-Q filed by EyePoint Inc.
- EyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
- EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
- SEC Form DEFA14A filed by EyePoint Inc.
Latest MTD
- Wolfe Research resumed coverage on Mettler-Toledo
- SEC Form SD filed by Mettler-Toledo International Inc.
- Head of Asia & Pacific Wong Ann Ping Richard was granted 103 shares, increasing direct ownership by 19% to 645 units (SEC Form 4)
- Head of PI, Retail, and GSC Wittorf Oliver was granted 87 shares, increasing direct ownership by 21% to 495 units (SEC Form 4)
- Chief Financial Officer Vadala Shawn was granted 291 shares, increasing direct ownership by 6% to 5,579 units (SEC Form 4)
- Head of Process Analytics Keller Gerry was granted 100 shares, increasing direct ownership by 63% to 259 units (SEC Form 4)
- President and CEO Kaltenbach Patrick was granted 810 shares, increasing direct ownership by 22% to 4,480 units (SEC Form 4)
- Chief Human Resources Officer Graham-Bryce Susan was granted 71 shares, increasing direct ownership by 16% to 517 units (SEC Form 4)
- Mettler-Toledo International Inc. filed SEC Form 8-K: Leadership Update
- Mettler-Toledo International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders